Privigen 10g
Biological
CSL Behring
Total Payments
$167,280
Transactions
2
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $167,280 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $167,280 | 2 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Double Blind Placebo Controlled Trial of IVIG for Skin Disease in Systemic Sclerosis (Scleroderma) | CSL Behring | $167,280 | 0 |
Top Doctors Receiving Payments for Privigen 10g
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Baltimore, MD | $167,280 | 2 |
Ad
Manufacturing Companies
- CSL Behring $167,280
Product Information
- Type Biological
- Total Payments $167,280
- Total Doctors 0
- Transactions 2
About Privigen 10g
Privigen 10g is a biological associated with $167,280 in payments to 0 healthcare providers, recorded across 2 transactions in the CMS Open Payments database. The primary manufacturer is CSL Behring.
Payment data is available from 2017 to 2017. In 2017, $167,280 was paid across 2 transactions to 0 doctors.
The most common payment nature for Privigen 10g is "Unspecified" ($167,280, 100.0% of total).
Privigen 10g is associated with 1 research study, including "Double Blind Placebo Controlled Trial of IVIG for Skin Disease in Systemic Sclerosis (Scleroderma)" ($167,280).